Q-omics provides the consensus-scored SIGLEC7 profile across patient tissues and cancer cell-line models. SIGLEC7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SIGLEC7 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SIGLEC7 RNA expression shows 21,419 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where SIGLEC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGLEC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGLEC7 survival associations across molecular data types. SIGLEC7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGLEC7 RNA expression–survival associations across cancer types. High SIGLEC7 expression shows unfavorable associations in UVM, LGG and STAD, but favorable associations in HNSC, CESC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SIGLEC7 RNA expression.
This table summarizes SIGLEC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SIGLEC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGLEC7 shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, THCA, HNSC and KIRP. The KIRC box plot shows higher SIGLEC7 RNA expression in tumor versus normal tissue (log2 FC = +1.627, t-test p < 0.001).
This table shows molecular features associated with SIGLEC7 in patient tissues and cancer cell lines. In patient samples, SIGLEC7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SIGLEC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
